Preclinical Evaluation of the Immunogenicity and Safety of an Inactivated Enterovirus 71 Candidate Vaccine

PLoS Neglected Tropical Diseases

Volumn 7, Issue 11, 2013, Pages

  Hwa, Shi Hsia ^a   Lee, Yock Ann ^a   Brewoo, Joseph N ^b   Partidos, Charalambos D ^b   Osorio, Jorge E ^b,c   Santangelo, Joseph D ^a  

^a Inviragen Pte Ltd   (Singapore)

^b Inviragen Inc   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; INACTIVATED ENTEROVIRUS 71 CANDIDATE VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; UNCLASSIFIED DRUG; VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG MEGADOSE; DRUG SAFETY; ELECTRON MICROSCOPY; ENTEROVIRUS 71; HISTOLOGY; IMMUNOGENICITY; LOW DRUG DOSE; MALE; MUSCLE ATROPHY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN PURIFICATION; RABBIT; SINGLE DRUG DOSE; TOXICOLOGY; WESTERN BLOTTING; ANIMAL; ENTEROVIRUS; IMMUNOLOGY; MOUSE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ENTEROVIRUS A, HUMAN; MICE; RABBITS; VACCINES, INACTIVATED;

EID: 84888229049     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002538     Document Type: Article

References (48)

1. Huang CC, Liu CC, Chang YC, Chen CY, Wang ST, et al. (1999) Neurologic complications in children with enterovirus 71 infection. N Engl J Med 341: 936-942.
2. Chang LY, Huang YC, Lin TY, (1998) Fulminant neurogenic pulmonary oedema with hand, foot, and mouth disease. Lancet 352: 367-368.
3. Ooi MH, Wong SC, Mohan A, Podin Y, Perera D, et al. (2009) Identification and validation of clinical predictors for the risk of neurological involvement in children with hand, foot, and mouth disease in Sarawak. BMC Infect Dis 9: 3.
4. Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, et al. (2010) Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 10 (11): 778-90.
5. McMinn PC, (2002) An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 26: 91-107.
6. (2012) WPRO Hand, Foot, and Mouth Disease Situation Update, 15 May 2012. Western Pacific Regional Office of the World Health Organization. pp. 4.
7. (2012) Updates on HFMD Situation in Singapore (23 May 2012). Hand, Foot & Mouth Disease: Updates: Singapore Ministry of Health.
8. Pallansch MA, Roos R (2007) Enteroviruses: polioviruses, coxsackieviruses, and newer enteroviruses. In: Knipe DM, Howley PM, Griffin DE, editors. Fields Virology. Philadelphia, PA Lippincott Williams & Wilkins. pp. 839-894.
9. Nagata N, Shimizu H, Ami Y, Tano Y, Harashima A, et al. (2002) Pyramidal and extrapyramidal involvement in experimental infection of cynomolgus monkeys with enterovirus 71. J Med Virol 67: 207-216.
10. Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, et al. (2009) Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med 15: 798-801.
11. Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, et al. (2009) Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med 15: 794-797.
12. Oberste MS, Maher K, Kilpatrick DR, Flemister MR, Brown BA, et al. (1999) Typing of human enteroviruses by partial sequencing of VP1. J Clin Microbiol 37: 1288-1293.
13. Lee MS, Tseng FC, Wang JR, Chi CY, Chong P, et al. (2012) Challenges to licensure of enterovirus 71 vaccines. PLoS Negl Trop Dis 6: e1737.
14. Brown BA, Oberste MS, Alexander JP Jr, Kennett ML, Pallansch MA, (1999) Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998. J Virol 73: 9969-9975.
15. Chan YF, Sam IC, Abubakar S, (2009) Phylogenetic designation of enterovirus 71 genotypes and subgenotypes using complete genome sequences. Infect Genet Evol 10 (3): 404-12.
16. Yoke-Fun C, AbuBakar S, (2006) Phylogenetic evidence for inter-typic recombination in the emergence of human enterovirus 71 subgenotypes. BMC Microbiol 6: 74.
17. Wang SM, Liu CC, Tseng HW, Wang JR, Huang CC, et al. (1999) Clinical spectrum of enterovirus 71 infection in children in southern Taiwan, with an emphasis on neurological complications. Clin Infect Dis 29: 184-190.
18. Ong KC, Devi S, Cardosa MJ, Wong KT, (2010) Formaldehyde-inactivated whole virus vaccine protects a murine model of Enterovirus 71 encephalomyelitis against disease. J Virol 84: 661-665.
19. Chong P, Hsieh SY, Liu CC, Chou AH, Chang JY, et al. (2012) Production of EV71 vaccine candidates. Hum Vaccin Immunother 8: 1775-83.
20. Chen HF, Chang MH, Chiang BL, Jeng ST, (2006) Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71. Vaccine 24: 2944-2951.
21. Meng T, Kolpe AB, Kiener TK, Chow VT, Kwang J, (2011) Display of VP1 on the surface of baculovirus and its immunogenicity against heterologous human enterovirus 71 strains in mice. PLoS ONE 6: e21757.
22. Liu JN, Wang W, Duo JY, Hao Y, Ma CM, et al. (2010) Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine 28: 7444-7451.
23. Chiu CH, Chu C, He CC, Lin TY, (2006) Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Microbes Infect 8: 1671-1678.
24. Tung WS, Bakar SA, Sekawi Z, Rosli R, (2007) DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vaccines Ther 5: 6.
25. Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, et al. (2008) Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 26: 1855-1862.
26. Arita M, Nagata N, Iwata N, Ami Y, Suzaki Y, et al. (2007) An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol 81: 9386-9395.
27. Mao Q, Dong C, Li X, Gao Q, Guo Z, et al. (2012) Comparative analysis of the immunogenicity and protective effects of inactivated EV71 vaccines in mice. PLoS ONE 7: e46043.
28. Chou AH, Liu CC, Chang JY, Lien SP, Guo MS, et al. (2012) Immunological Evaluation and Comparison of Different EV71 Vaccine Candidates. Clin Dev Immunol 2012: 831282.
29. Li YP, Liang ZL, Gao Q, Huang LR, Mao QY, et al. (2012) Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial. Vaccine 30: 3295-3303.
30. Zhu FC, Meng FY, Li JX, Li XL, Mao QY, et al. (2013) Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 381: 2024-2032.
31. Cheng A, Fung CP, Liu CC, Lin YT, Tsai HY, et al. (2013) A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine. Vaccine 31: 2471-2476.
32. Bahnemann HG, (1990) Inactivation of viral antigens for vaccine preparation with particular reference to the application of binary ethylenimine. Vaccine 8: 299-303.
33. Yu CK, Chen CC, Chen CL, Wang JR, Liu CC, et al. (2000) Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice. J Biomed Sci 7: 523-528.
34. Liu CC, Guo MS, Lin FH, Hsiao KN, Chang KH, et al. (2011) Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system. PLoS One 6: e20005.
35. Shingler KL, Yoder JL, Carnegie MS, Ashley RE, Makhov AM, et al. (2013) The Enterovirus 71 A-particle Forms a Gateway to Allow Genome Release: A CryoEM Study of Picornavirus Uncoating. PLoS Pathog 9: e1003240.
36. Curry S, Chow M, Hogle JM, (1996) The poliovirus 135S particle is infectious. J Virol 70: 7125-7131.
37. Verdier F, (2002) Non-clinical vaccine safety assessment. Toxicology 174: 37-43.
38. Verdier F, Burnett R, Michelet-Habchi C, Moretto P, Fievet-Groyne F, et al. (2005) Aluminium assay and evaluation of the local reaction at several time points after intramuscular administration of aluminium containing vaccines in the Cynomolgus monkey. Vaccine 23: 1359-1367.
39. Wang YF, Chou CT, Lei HY, Liu CC, Wang SM, et al. (2004) A mouse-adapted enterovirus 71 strain causes neurological disease in mice after oral infection. J Virol 78: 7916-7924.
40. Wang W, Duo J, Liu J, Ma C, Zhang L, et al. (2011) A mouse muscle-adapted enterovirus 71 strain with increased virulence in mice. Microbes Infect 13: 862-870.
41. Huang SW, Wang YF, Yu CK, Su IJ, Wang JR, (2012) Mutations in VP2 and VP1 capsid proteins increase infectivity and mouse lethality of enterovirus 71 by virus binding and RNA accumulation enhancement. Virology 422: 132-143.
42. Khong WX, Yan B, Yeo H, Tan EL, Lee JJ, et al. (2011) A non mouse-adapted Enterovirus 71 (EV71) strain exhibits neurotropism causing neurological manifestations in a novel mouse model of EV71 infection. J Virol 86 (4): 2121-31.
43. Caine EA, Partidos CD, Santangelo JD, Osorio JE, (2013) Adaptation of enterovirus 71 to adult interferon deficient mice. PLoS ONE 8: e59501.
44. Huang ML, Chiang PS, Chia MY, Luo ST, Chang LY, et al. (2013) Cross-reactive neutralizing antibody responses to enterovirus 71 infections in young children: implications for vaccine development. PLoS Negl Trop Dis 7: e2067.
45. Chen Y, Li C, He D, Cheng T, Ge S, et al. (2013) Antigenic analysis of divergent genotypes human Enterovirus 71 viruses by a panel of neutralizing monoclonal antibodies: current genotyping of EV71 does not reflect their antigenicity. Vaccine 31: 425-430.
46. Kung SH, Wang SF, Huang CW, Hsu CC, Liu HF, et al. (2007) Genetic and antigenic analyses of enterovirus 71 isolates in Taiwan during 1998-2005. Clin Microbiol Infect 13: 782-787.
47. Mizuta K, Aoki Y, Suto A, Ootani K, Katsushima N, et al. (2009) Cross-antigenicity among EV71 strains from different genogroups isolated in Yamagata, Japan, between 1990 and 2007. Vaccine 27: 3153-3158.
48. Lee BY, Wateska AR, Bailey RR, Tai JH, Bacon KM, et al. (2010) Forecasting the economic value of an Enterovirus 71 (EV71) vaccine. Vaccine 28: 7731-7736.